Rapid optimisation of mRNA-LNP using microfluidics: Equipment, formulation and process

Interest in nanotechnology, including both polymeric and lipidic nanoparticles, has grown significantly in the last decade. The tremendous success of mRNA-lipid nanoparticle (LNP)-based vaccines during the COVID-19 pandemic has led to further explosive growth in development and created new opportunities in this area. The unprecedented speed of development of the COVID-19 LNP-based vaccines was, to a large extent, built upon foundational work performed over the last 10–15 years in LNP platform development.